Vistagen Therapeutics (VTGN)

Vistagen Therapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.

Download CSV

2.5M

Short interest

settlement 2026-10-15

2.2

Days to cover

+1.2 days vs prior

62.5%

Short share of volume

2026-11-02

463

Fails to deliver

settlement 2026-10-13

Thu 12 Nov

Next earnings

estimated date

Insider flow, 90 days

0 buys, 0 sells

As of 2026-11-02.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 15 October 2026, short interest in VTGN is 2,472,435 shares, down 234,585 shares over the last month. Over the last 48 readings it ranged from 409,632 shares (13 December 2024) to 3,750,912 shares (30 September 2026). At the reported average volume of 1.1M shares a day that is 2.2 days to cover.

Embed this chart.The embed keeps its attribution line.

<iframe src="https://xoomar.com/embed/stocks/vtgn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

Preview Dark previewAdd ?theme=dark to the src for a dark chart.

Settlement	Shares short	Change	Avg daily volume	Days to cover
2026-10-15	2,472,435	-34.1%	1,137,394	2.17
2026-09-30	3,750,912	+38.6%	55,161,968	1.00
2026-09-15	2,707,020	+27.3%	354,148	7.64
2026-08-31	2,126,593	+8.9%	762,770	2.79
2026-08-14	1,952,907	-2.6%	13,056,772	1.00
2026-07-31	2,005,860	+25.7%	823,269	2.44
2026-07-15	1,596,248	+0.3%	3,306,171	1.00
2026-06-30	1,591,673	-6.7%	5,765,083	1.00
2026-06-15	1,705,050	-15.6%	705,956	2.42
2026-05-29	2,020,399	+12.4%	503,202	4.02
2026-05-15	1,797,894	+2.2%	1,120,681	1.60
2026-04-30	1,758,461	+2.8%	1,133,637	1.55
2026-04-15	1,711,402	+21.3%	628,257	2.72
2026-03-31	1,410,489	+9.1%	410,005	3.44
2026-03-13	1,293,080	-14.9%	535,758	2.41
2026-02-27	1,519,296	-5.6%	727,078	2.09
2026-02-13	1,609,597	-20.9%	1,300,966	1.24
2026-01-30	2,036,211	-16.6%	1,051,059	1.94
2026-01-15	2,441,031	-27.9%	1,563,145	1.56
2025-12-31	3,385,220	+88.9%	10,198,793	1.00
2025-12-15	1,791,894	+40.6%	992,442	1.81
2025-11-28	1,274,319	-16.0%	1,113,436	1.14
2025-11-14	1,517,368	+11.8%	428,488	3.54
2025-10-31	1,357,492	+1.4%	478,858	2.83
2025-10-15	1,338,753	-0.4%	583,677	2.29
2025-09-30	1,343,811	+15.7%	710,694	1.89
2025-09-15	1,161,410	+22.7%	331,462	3.50
2025-08-29	946,396	+55.7%	431,433	2.19
2025-08-15	607,798	+27.4%	719,889	1.00
2025-07-31	477,221	-5.0%	530,935	1.00
2025-07-15	502,316	+8.8%	381,068	1.32
2025-06-30	461,849	-3.4%	248,809	1.86
2025-06-13	478,074	-10.4%	129,514	3.69
2025-05-30	533,808	+2.1%	199,573	2.67
2025-05-15	522,635	+9.7%	92,868	5.63
2025-04-30	476,262	-8.0%	106,124	4.49
2025-04-15	517,544	-3.4%	130,260	3.97
2025-03-31	535,628	-9.9%	130,189	4.11
2025-03-14	594,670	-8.6%	122,639	4.85
2025-02-28	650,436	-2.9%	175,720	3.70
2025-02-14	669,798	-10.0%	232,204	2.88
2025-01-31	744,387	+13.1%	124,827	5.96
2025-01-15	658,063	+46.3%	322,021	2.04
2024-12-31	449,967	+9.8%	466,383	1.00
2024-12-13	409,632	-3.7%	197,847	2.07
2024-11-29	425,445	-0.5%	206,923	2.06
2024-11-15	427,512	-19.1%	257,101	1.66
2024-10-31	528,162	-18.1%	256,922	2.06

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 2 November 2026, the short share of VTGN volume is 62.5%, up 18.1 points over the last five sessions. Over the last 30 readings it ranged from 23.5% (13 October 2026) to 68.7% (21 October 2026). The latest reading is 14.6 points above the 30-session average of 47.8%, on 432K shares reported.

Date	Short volume	Total volume	Short share	Exempt
2026-11-02	270K	432K	62.5%	0
2026-10-30	130K	256K	50.8%	0
2026-10-29	189K	280K	67.7%	0
2026-10-28	276K	480K	57.5%	6,541
2026-10-27	128K	268K	48.0%	0
2026-10-26	155K	350K	44.4%	0
2026-10-23	406K	778K	52.2%	0
2026-10-22	182K	462K	39.5%	9,492
2026-10-21	193K	280K	68.7%	0
2026-10-20	125K	322K	38.9%	0
2026-10-19	264K	762K	34.6%	7,900
2026-10-16	194K	284K	68.3%	0
2026-10-15	310K	637K	48.6%	0
2026-10-14	241K	603K	40.0%	1
2026-10-13	172K	730K	23.5%	400
2026-10-12	222K	433K	51.3%	300
2026-10-09	111K	238K	46.8%	0
2026-10-08	194K	378K	51.3%	2,746
2026-10-07	111K	359K	30.9%	2,789
2026-10-06	328K	842K	39.0%	201
2026-10-05	603K	1.3M	45.0%	42,600
2026-10-02	352K	785K	44.9%	4,800
2026-10-01	593K	1.3M	45.4%	2,570
2026-09-30	467K	1.4M	33.1%	5,101
2026-09-29	597K	1.4M	43.6%	33,692
2026-09-28	2.3M	4.4M	51.8%	355,298
2026-09-25	1.1M	2.8M	40.7%	132,599
2026-09-24	6.5M	11.2M	57.9%	1,229,730
2026-09-23	134.9M	233.0M	57.9%	862,293
2026-09-22	1.5M	3.0M	50.6%	206

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 13 October 2026, the fails-to-deliver balance in VTGN is 463 shares, down 170,775 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (21 May 2026) to 2,641,884 shares (24 September 2026). The latest reading sits at the bottom of that range.

Settlement	Shares failed	Price	Value
2026-10-13	463	$0.23	$106
2026-09-29	171,238	$0.30	$51K
2026-09-25	383,160	$0.30	$115K
2026-09-24	2,641,884	$0.37	$977K
2026-09-10	13,408	$0.24	$3K
2026-09-09	561	$0.24	$135
2026-09-08	17,104	$0.24	$4K
2026-09-01	17,391	$0.26	$5K
2026-08-26	97,244	$0.25	$24K
2026-08-19	33,087	$0.24	$8K
2026-08-17	44	$0.27	$12
2026-08-12	367	$0.27	$99
2026-08-11	18,583	$0.26	$5K
2026-08-07	4,811	$0.28	$1K
2026-08-05	153,717	$0.30	$46K
2026-08-04	24,312	$0.25	$6K
2026-08-03	43,229	$0.24	$10K
2026-07-31	6,852	$0.24	$2K
2026-07-29	100,990	$0.23	$23K
2026-07-28	77,614	$0.23	$18K
2026-07-27	83,848	$0.23	$19K
2026-07-10	1,000	$0.25	$250
2026-07-07	33,266	$0.25	$8K
2026-07-01	208,725	$0.23	$48K
2026-06-30	1,719	$0.76	$1K
2026-05-29	40,349	$0.63	$25K
2026-05-21	1	$0.64	$1
2026-05-15	2	$0.65	$1
2026-05-06	1,434	$0.60	$860
2026-05-01	3	$0.61	$2

Insider trades

SEC Form 4, newest first. JSON

No open-market insider trades were reported for VTGN in the last 90 days. The most recent filings are listed below. Latest filing: Tressler Nick B. (Chief Financial Officer) on 2026-06-30.

Date	Insider	Title	Type	Shares	Price	Value	Owned after
2026-06-30	Tressler Nick B.	Chief Financial Officer	Grant	12K	$0.19	$2K	12K
2026-06-30	Singh Shawn	President and CEO	Grant	37K	$0.19	$7K	55K
2026-06-30	Adler Reid G.	Chief Legal Officer	Grant	37K	$0.19	$7K	61K
2025-12-31	Prince Joshua S.	Chief Operating Officer	Grant	4K	$0.56	$2K	15K
2025-06-30	Singh Shawn	President and CEO	Grant	8K	$1.70	$13K	18K
2025-06-30	Prince Joshua S.	Chief Operating Officer	Grant	5K	$1.70	$8K	11K
2025-06-30	Anderson Cynthia Lynn	CHIEF FINANCIAL OFFICER	Grant	7K	$1.70	$11K	13K
2025-06-30	Adler Reid G.	Chief Legal Officer	Grant	8K	$1.70	$13K	24K
2024-12-31	Anderson Cynthia Lynn	CHIEF FINANCIAL OFFICER	Grant	3K	$2.51	$7K	6K
2024-12-31	Prince Joshua S.	Chief Operating Officer	Grant	3K	$2.51	$8K	6K
2024-06-28	Singh Shawn	CHIEF EXECUTIVE OFFICER	Grant	5K	$2.96	$14K	10K
2024-06-28	Adler Reid G.	CHF CORP DEVEL OFF, GEN COUNS	Grant	5K	$2.96	$14K	17K
2024-06-28	Anderson Cynthia Lynn	CHIEF FINANCIAL OFFICER	Grant	4K	$2.96	$11K	4K
2024-06-28	Prince Joshua S.	Chief Operating Officer	Grant	3K	$2.96	$8K	3K
2023-12-29	Singh Shawn	CHIEF EXECUTIVE OFFICER	Grant	167	$1.72	$287	6K
2023-12-29	Adler Reid G.	CHF CORP DEVEL OFF, GEN COUNS	Grant	167	$1.72	$287	12K
2023-08-07	COMMODORE CAPITAL LP	TenPercentOwner	Buy	776K	$23.15	$18.0M	1.6M
2023-06-30	DOTSON JERROLD DUANE	VP, CFO	Grant	167	$1.59	$266	4K
2023-06-30	Adler Reid G.	CHIEF LEGAL OFFICER	Grant	167	$1.59	$266	11K
2023-06-30	Singh Shawn	CHIEF EXECUTIVE OFFICER	Grant	167	$1.59	$266	5K
2022-12-30	Singh Shawn	CHIEF EXECUTIVE OFFICER	Grant	5K	$0.09	$450	159K
2022-12-30	DOTSON JERROLD DUANE	VP, CFO AND SECRETARY	Grant	5K	$0.09	$450	105K
2022-08-18	GIN JERRY B	Director	Buy	100K	$0.18	$18K	100K
2022-08-18	GIN JERRY B	Director	Buy	100K	$0.18	$18K	100K
2022-08-17	Singh Shawn	CHIEF EXECUTIVE OFFICER	Buy	600K	$0.17	$102K	626K
2022-08-17	Adler Reid G.	CHIEF LEGAL OFFICER	Buy	300K	$0.17	$51K	335K
2022-07-30	DOTSON JERROLD DUANE	VP, CFO AND SECRETARY	Grant	5K	$0.75	$4K	100K
2022-07-12	VHCP Management II, LLC	TenPercentOwner	Sell	60K	$0.89	$53K	20.6M
2022-06-30	Smith Mark Alan	CHIEF MEDICAL OFFICER	Grant	5K	$0.75	$4K	20K
2022-06-30	Singh Shawn	CHIEF EXECUTIVE OFFICER	Grant	5K	$0.75	$4K	154K
2022-05-12	Singh Shawn	CHIEF EXECUTIVE OFFICER	Exercise or conversion	100K	$1.00	$100K	149K
2022-01-11	DOTSON JERROLD DUANE	VP, CFO AND SECRETARY	Exercise or conversion	19K	$1.00	$19K	95K
2021-12-31	Singh Shawn	CHIEF EXECUTIVE OFFICER	Grant	4K	$1.66	$6K	49K
2021-12-31	Unknown	PRES./CHIEF SCIENTIFIC OFFICER	Grant	4K	$1.66	$6K	65K
2021-12-31	DOTSON JERROLD DUANE	VP, CFO AND SECRETARY	Grant	4K	$1.66	$6K	76K
2021-12-31	Smith Mark Alan	CHIEF MEDICAL OFFICER	Grant	3K	$1.66	$4K	15K
2021-09-07	DOTSON JERROLD DUANE	VP, CFO AND SECRETARY	Sell	30K	$3.13	$94K	73K
2021-09-02	SNODGRASS H. RALPH	PRES./CHIEF SCIENTIFIC OFFICER	Gift	1K	$0.00	$0	61K
2021-08-23	SNODGRASS H. RALPH	PRES./CHIEF SCIENTIFIC OFFICER	Gift	740	$0.00	$0	34K
2021-08-17	SNODGRASS H. RALPH	PRES./CHIEF SCIENTIFIC OFFICER	Buy	4K	$2.73	$10K	35K
2021-06-30	Singh Shawn	CHIEF EXECUTIVE OFFICER	Grant	5K	$1.95	$10K	45K
2021-06-30	Smith Mark Alan	CHIEF MEDICAL OFFICER	Grant	2K	$1.95	$4K	12K
2021-06-30	SNODGRASS H. RALPH	PRES./CHIEF SCIENTIFIC OFFICER	Grant	3K	$1.95	$7K	91K
2021-06-30	DOTSON JERROLD DUANE	VP, CFO AND SECRETARY	Grant	3K	$1.95	$6K	13K
2021-06-30	DOTSON JERROLD DUANE	VP, CFO AND SECRETARY	Exercise or conversion	1K	$1.50	$2K	14K
2021-06-30	DOTSON JERROLD DUANE	VP, CFO AND SECRETARY	Exercise or conversion	79K	$1.00	$79K	93K
2021-06-30	DOTSON JERROLD DUANE	VP, CFO AND SECRETARY	Exercise or conversion	10K	$0.40	$4K	103K
2021-04-23	Singh Shawn	CHIEF EXECUTIVE OFFICER	Exercise or conversion	5K	$1.50	$8K	40K
2021-03-19	SAXE JON S	Director	Exercise or conversion	3K	$1.50	$4K	6K
2021-03-19	Underdown Brian J.	Director	Exercise or conversion	3K	$1.50	$4K	3K
2020-12-31	SNODGRASS H. RALPH	PRES./CHIEF SCIENTIFIC OFFICER	Grant	5K	$0.45	$2K	88K
2020-12-31	Smith Mark Alan	CHIEF MEDICAL OFFICER	Grant	5K	$0.45	$2K	10K
2020-12-31	DOTSON JERROLD DUANE	VP, CFO AND SECRETARY	Grant	5K	$0.45	$2K	10K
2020-12-31	Unknown	CHIEF EXECUTIVE OFFICER	Grant	5K	$0.45	$2K	35K
2020-08-21	SAXE JON S	Director	Buy	30K	$0.69	$21K	50K
2020-06-30	Singh Shawn	CHIEF EXECUTIVE OFFICER	Grant	5K	$0.45	$2K	30K
2020-06-30	DOTSON JERROLD DUANE	VP, CFO AND SECRETARY	Grant	5K	$0.45	$2K	5K
2020-06-30	Smith Mark Alan	CHIEF MEDICAL OFFICER	Grant	5K	$0.45	$2K	5K
2020-06-30	SNODGRASS H. RALPH	PRES./CHIEF SCIENTIFIC OFFICER	Grant	5K	$0.45	$2K	68K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

7 holders report 5% or more of VTGN in their latest filing, all on Schedule 13G (passive). The largest reported stake is Commodore Capital LP at 9.9% of the class (4,244,590 shares), filed 2026-08-14.

Filed	Form	Holder	Shares	Of class	Event
2026-08-14	13G/Ano. 2	Chen Yuindividual	3.0M	6.7%	2026-06-30
2026-08-14	13G/Ano. 2	TCG Crossover GP II, LLCother entity	2.2M	5.1%	2026-06-30
2026-08-14	13G/Ano. 2	TCG Crossover Fund II, L.P.partnership	2.2M	5.1%	2026-06-30
2026-08-14	13G/Ano. 2	TCG Crossover Fund I, L.P.partnership	740K	1.8%	2026-06-30
2026-08-14	13G/Ano. 2	TCG Crossover GP I, LLCother entity	740K	1.8%	2026-06-30
2026-08-14	13G/Ano. 2	ORBIMED CAPITAL LLCinvestment adviser	0	0.0%	2026-06-30
2026-08-14	13G/Ano. 2	ORBIMED ADVISORS LLCinvestment adviser	0	0.0%	2026-06-30
2026-08-14	13G/Ano. 3	Commodore Capital LPinvestment adviser, partnership	4.2M	9.9%	n/a
2026-08-14	13G/Ano. 3	Commodore Capital Master LPpartnership	4.2M	9.9%	n/a
2026-08-14	13G/Ano. 3	Robert Egen Atkinsonparent holding company, individual	4.2M	9.9%	n/a
2026-08-14	13G/Ano. 3	Michael Kramarzparent holding company, individual	4.2M	9.9%	n/a
2026-02-17	13G/Ano. 1	JANUS HENDERSON GROUP PLCparent holding company	0	0.0%	2025-12-31
2026-02-17	13G/Ano. 7	Dr. Jeffrey R. Jay, M.D.parent holding company, individual	2.1M	5.0%	2025-12-31
2026-02-17	13G/Ano. 7	Ms. Lillian Nordahlparent holding company, individual	2.1M	5.0%	2025-12-31
2026-02-17	13G/Ano. 7	Great Point Partners, LLCinvestment adviser, other entity	2.1M	5.0%	2025-12-31
2026-02-17	13G/Ano. 2	StemPoint Capital LPinvestment adviser	617K	1.5%	2025-12-31
2026-02-17	13G/Ano. 2	StemPoint Capital Management GP LLCother entity	617K	1.5%	2025-12-31
2026-02-17	13G/Ano. 2	Michelle Rossparent holding company, individual	617K	1.5%	2025-12-31
2026-02-13	13G/Ano. 3	Daniel Mackparent holding company	2.0M	4.7%	2025-12-31
2026-02-13	13G/Ano. 3	Nantahala Capital Management, LLCinvestment adviser	2.0M	4.7%	2025-12-31
2026-02-13	13G/Ano. 3	Wilmot B. Harkeyparent holding company	2.0M	4.7%	2025-12-31
2026-01-30	13G/Ano. 2	The Vanguard Groupinvestment adviser	1.8M	4.6%	2025-12-31

13F holders

Tracked managers holding VTGN at their latest 13F. JSON

3 of the 30 tracked managers held VTGN at their latest 13F, $372K in total at quarter-end prices. Two Sigma Investments is the largest at $192K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 0 cut.

Fund	Quarter	Shares	Value	Of portfolio	Change in shares
Two Sigma Investments	2026-06-30	848K	$192K	0.00%	+378K
Renaissance Technologies	2026-06-30	731K	$165K	0.00%	+439K
Citadel Advisors	2026-06-30	69K	$16K	0.00%	new

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

What this page is

Vistagen Therapeutics in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows Vistagen Therapeutics (VTGN), SEC CIK 1411685, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest: FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
Daily short volume: FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
Fails to deliver: SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
Large holders: SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
13F holders: SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Earnings dates: SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-06-15.JSON and CSV
Insider trades: SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-06-30.JSON and CSV
Company record: EDGAR filing index for CIK 1411685Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits: 10 requests a minute without a key, 30 with a free key from a free account.

How to read it

Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as pharmaceutical preparations

Other company pages

Datasets

Frequently Asked Questions

How much of VTGN is sold short?

2,472,435 shares were held short at the 2026-10-15 settlement, 2.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.

What is VTGN's daily short volume?

On 2026-11-02, 270,015 of the 432,145 VTGN shares reported to FINRA were sold short, 62.5% of the day's reported volume. Short volume is a flow for one day, not a position.

Does VTGN have fails to deliver?

The SEC's latest file shows 463 VTGN shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.

Are VTGN insiders buying or selling?

No open-market insider trades were reported for VTGN in the last 90 days. The most recent filings are listed below. Latest filing: Tressler Nick B. (Chief Financial Officer) on 2026-06-30.

Who owns 5% or more of VTGN?

Which tracked 13F managers own VTGN?

3 of the 30 tracked 13F managers held VTGN shares at their latest filing, $372K in all. The largest: Two Sigma Investments (848K shares, $192K), Renaissance Technologies (731K shares, $165K), Ken Griffin's Citadel Advisors (69K shares, $16K).

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.